BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Read More
Source link
La reacción devastadora de Messi tras fallar su penal ante Egipto
IE 11 no es compatible. Para una experiencia óptima, visite nuestro sitio en otro navegador. SIGUIENTE Egipto anota, Hassan pide calma y el banquillo rompe en celebración 01:31 Messi falla…






